• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc. (Amendment)

    2/14/22 4:37:09 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRCA alert in real time by email
    SC 13G/A 1 vrca-sc13ga_123121.htm AMENDMENT TO FORM SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND

    (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

     

    (Amendment No. 3)*

    Verrica Pharmaceuticals Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    9251 1W 108

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 9251 1W 108 13G Page 2 of 8 Pages
    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Paul B. Manning

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    9,145,8581

    6

    SHARED VOTING POWER

    1,481,7192

    7

    SOLE DISPOSITIVE POWER

    9,145,8581

    8

    SHARED DISPOSITIVE POWER

    1,481,7192

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,627,5773

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    38.6%4

    12

    TYPE OF REPORTING PERSON*

    IN

         
      1 Consists of: (i) 7,754,783 shares of the Issuer’s common stock held directly by Paul B. Manning; (ii) 1,134,441 shares of the Issuer’s common stock held by Paul and Diane Manning, JTWROS; and (iii) 256,634 shares of the Issuer’s common stock held by PBM Capital Investments, LLC.
      2 Consists of 1,481,719 shares of the Issuer's common stock held by BKB Growth Investments, LLC.
      3 Consists of: (i) 7,754,783 shares of the Issuer's common stock held directly by Paul B. Manning; (ii) 1,134,441 shares of the Issuer's common stock held by Paul and Diane Manning, JTWROS; and (iii) 256,634 shares of the Issuer's common stock held by PBM Capital Investments, LLC; and (iv) 1,481,719 shares of the Issuer's common stock held by BKB Growth Investments, LLC.
      4 This percentage is calculated based upon 27,519,053 shares of the Issuer’s common stock outstanding as of November 4, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 11, 2021.

     

     

    CUSIP No. 9251 1W 108 13G Page 3 of 8 Pages
    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    PBM Capital Investments, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    256,634

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    256,634

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    256,634

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.9%6

    12

    TYPE OF REPORTING PERSON*

    OO

      6 This percentage is calculated based upon 27,519,053 shares of the Issuer’s common stock outstanding as of November 4, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 11, 2021.

     

     

    CUSIP No. 9251 1W 108 13G Page 4 of 8 Pages
    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    BKB Growth Investments, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    .

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    1,481,719

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    1,481,719

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,481,719

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.4%7

    12

    TYPE OF REPORTING PERSON*

    OO

      7 This percentage is calculated based upon 27,519,053 shares of the Issuer’s common stock outstanding as of November 4, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 11, 2021.

     

     

    CUSIP No. 9251 1W 108 13G Page 5 of 8 Pages

    Item 1.

     

      (a) Name of Issuer

    Verrica Pharmaceuticals Inc.

      (b) Address of Issuer’s Principal Executive Offices

    44 West Gay Street, Suite 400
    West Chester, PA 19380

    Item 2.

      (a) Name of Person Filing

    Paul B. Manning
    PBM Capital Investments, LLC
    BKB Growth Investments, LLC

      (b) Address of Principal Business Office or, if none, Residence

    c/o PBM Capital Group, LLC
    200 Garrett Street, Suite S
    Charlottesville, VA 22902

      (c) Citizenship

    Paul B Manning is a United States Citizen.
    PBM Capital Investments, LLC is a Delaware limited liability company.
    BKB Growth Investments, LLC is a Delaware limited liability company.

      (d) Title of Class of Securities

    Common Stock

      (e) CUSIP Number

    9251 1W 108

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.
    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: .

     

     

    CUSIP No. 9251 1W 108 13G Page 6 of 8 Pages
      Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: See responses to Item 9 on the attached cover pages.
    (b) Percent of class: See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.
      (ii) Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.
      (iii) Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.
      (iv) Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.
           

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

      Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

      Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

     

    CUSIP No. 9251 1W 108 13G Page 7 of 8 Pages
      Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable

      Item 8. Identification and Classification of Members of the Group.

    Not Applicable

      Item 9. Notice of Dissolution of Group.

    Not Applicable

      Item 10. Certification

    Not Applicable.

     

     

    CUSIP No. 9251 1W 108 13G Page 8 of 8 Pages

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2022    
         
      /s/ Paul B. Manning  
      Paul B. Manning  
         
      BKB Growth Investments, LLC  
         
      By Tiger Lily Capital, LLC, its manager  
         
      By: /s/ Paul B. Manning  
      Name: Paul B. Manning  
      Title: Manager  
           
      By: /s/ Bradford Manning  
      Name: Bradford Manning  
      Title: Manager  
           
      PBM Capital Investments, LLC  
         
      By: PBM Capital Group, LLC, its manager  
         
      By: /s/ Paul B. Manning  
      Name: Paul B. Manning  
      Title: Chief Executive Officer  

     

    Get the next $VRCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRCA

    DatePrice TargetRatingAnalyst
    11/6/2024Buy → Neutral
    H.C. Wainwright
    11/5/2024Outperform → Sector Perform
    RBC Capital Mkts
    7/25/2023$10.00Hold → Buy
    Needham
    3/22/2023$10.00Buy
    Jefferies
    2/13/2023$4.00 → $11.00Sector Perform → Outperform
    RBC Capital Mkts
    5/25/2022$16.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    3/10/2022$20.00Buy
    Brookline Capital
    3/3/2022$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $VRCA
    Leadership Updates

    Live Leadership Updates

    See more
    • Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

      – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi

      11/4/24 4:05:00 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

      WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a

      8/10/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

      Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te

      7/9/21 7:30:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

      WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Invest

      4/30/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

      – Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicato

      4/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verrica Pharmaceuticals downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral

      11/6/24 6:25:52 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform

      11/5/24 6:29:20 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals upgraded by Needham with a new price target

      Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00

      7/25/23 7:35:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Financials

    Live finance-specific insights

    See more
    • Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

      WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of

      5/7/25 8:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

      WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut

      3/3/25 7:00:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

      - Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i

      8/14/24 7:45:00 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Corcoran Gavin

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:32:51 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Corcoran Gavin claimed ownership of 20 shares (SEC Form 3)

      3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      4/2/25 4:31:50 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CMO Rosenberg Noah L.

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      3/26/25 7:10:45 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stalfort John A Iii bought 1,123,595 shares and received a gift of 50,000 shares, increasing direct ownership by 168% to 1,873,800 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:08 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Rieger Jayson bought 280,898 shares and received a gift of 50,000 shares, increasing direct ownership by 60% to 882,826 units (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:13 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Manning Paul B bought 22,921,348 shares and gifted 450,000 shares (SEC Form 4)

      4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

      11/26/24 4:15:07 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Verrica Pharmaceuticals Inc.

      DEFR14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/30/25 6:06:32 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Verrica Pharmaceuticals Inc.

      8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/25/25 4:21:12 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Verrica Pharmaceuticals Inc.

      DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

      4/22/25 7:18:16 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

      Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

      7/21/23 4:54:32 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      12/9/24 6:22:49 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

      SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/26/24 4:15:26 PM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

      SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

      11/14/24 9:32:46 AM ET
      $VRCA
      Biotechnology: Pharmaceutical Preparations
      Health Care